Sofia Gronskaia | Endocrine Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Mrs. Sofia Gronskaia | Endocrine Pharmacology | Best Researcher Award

The National Medical Research Center for Endocrinology | Russia

Mrs. Sofia Gronskaia is a highly accomplished medical professional and researcher specializing in endocrinology, molecular genetics, and rare endocrine disorders. She completed her MD with honors from Sechenov University, followed by a residency in endocrinology at the National Medical Research Center for Endocrinology. She further earned a Ph.D. in endocrinology with a thesis focused on FGF-23-secreting tumors, reflecting her dedication to advancing knowledge in rare endocrine and skeletal disorders. Currently, she is pursuing a residency in genetics at the Research Center for Medical Genetics, combining clinical expertise with cutting-edge genomic research to unravel complex endocrine pathologies.Mrs. Gronskaia has undertaken extensive training in dietetics, molecular biology, genetics, and next-generation sequencing data analysis at prestigious institutions, including the Moscow Institute of Physics and Technology and the Research Center for Medical Genetics. Professionally, she has contributed as a Junior Research Fellow in Molecular Oncoendocrinology and currently serves as an endocrinologist at the National Medical Research Center for Endocrinology. Her research endeavors are extensive, serving as Principal Investigator on the RSF Grant for integrating genomic and transcriptomic data to improve early diagnosis and therapeutic target identification in endocrine tumors with paraneoplastic syndrome. She has also contributed to state assignments on developing personalized diagnostic approaches for osteoporosis secondary to endocrinopathies and exploring novel technologies for rare skeletal diseases.Her pioneering work is reflected in publications across leading journals. Notable works include A registry for patients with chronic hypoparathyroidism in Russian adults in Endocrine Connections, Denosumab for osteoporosis in patients with primary hyperparathyroidism and mild-to-moderate renal insufficiency in Endocrine, and Bone Health ECHO Case Report: Rare cases of hypophosphatemia and low-traumatic fractures in patients with type 1 diabetes mellitus in the Journal of Clinical Densitometry.

Profile: Orcid

Featured Publications

Gronskaia, S. A., Belaya, Z. E., Rozhinskaya, L. Y., Melnichenko, G. A., Dubovitskaya, T. A., Mamedova, E. O., Rodionova, S. S., Buklemishev, Y. V., Pigarova, E. A., & Degtyarev, M. V. (2023). Clinical features, diagnostics and treatment of FGF23 secreting tumors: Series of 40 clinical cases. Problems of Endocrinology.

Gronskaia, S. A., Golounina, O. O., Buklemishev, Y. V., Khairieva, A. V., Degtyarev, M. V., Rozhinskaya, L. Y., & Belaya, Z. E. (2023). A clinical case of phosphopenic osteomalacia due to paraneoplastic secretion of metastatic prostate cancer. Osteoporosis and Bone Diseases.

Gronskaia, S., Belaya, Z., Rozhinskaya, L., Mamedova, E., Vorontsova, M., Solodovnikov, A., Golounina, O., & Melnichenko, G. (2022). Denosumab for osteoporosis in patients with primary hyperparathyroidism and renal insufficiency. ResearchSquare.

Gronskaia, S. A., Belaya, Z. E., & Melnichenko, G. A. (2022). FGF23 tumor-induced osteomalacia, ФРФ23-индуцированная остеомаляция опухолевого генеза. Problemy Endokrinologii.

Golounina, O. O., Pavlova, M. G., Gronskaia, S. A., Kaznacheeva, T. V., Dzeranova, L. K., Belaya, J. E., & Fadeev, V. V. (2021). Cushing’s syndrome and pregnancy: Diagnostic, treatment and management tactics. Russian Bulletin of Obstetrician-Gynecologist.

Gronskaia, S. A., Belaya, Z. E., Rozhinskaya, L. Y., Melnichenko, G. A., & others. (n.d.). A registry for patients with chronic hypoparathyroidism in Russian adults. Endocrine Connections. [Full citation details needed for DOI]

Efthalia Moustakli | Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Efthalia Moustakli | Pharmacology | Best Researcher Award

Dr. Efthalia Moustakli at University of Ioannina, School of Health Sciences, Greece.

Dr. Efthalia Moustakli, a PhD-trained biologist, excels in medical genetics, molecular biology, and bioinformatics. Currently a postdoctoral researcher and adjunct professor, she integrates clinical, wet-lab, and computational techniques to drive real-world healthcare innovation. With extensive experience in translational science and academic mentorship, she bridges the gap between research and clinical application. Her dedication to advancing reproductive medicine and aging research is reflected in 30+ high-impact publications. Recognized for academic excellence and research leadership, she exemplifies commitment to impactful science and interdisciplinary collaboration across education, technology, and medicine.

Publication Profile 

Google Scholar

Education

Dr. Efthalia Moustakli earned her PhD in Medical Genetics from the University of Ioannina, Greece, with her dissertation graded “Excellent” and focused on telomere and mitochondrial recombination in spermatozoa. She previously completed an Integrated Master’s in Biological Applications and Technology, also from the University of Ioannina, where her thesis on genetic abnormalities. Her academic journey reflects a strong foundation in genetics, genomics, and reproductive biology, complemented by international training in Germany, showcasing her commitment to advancing precision and reproductive medicine through rigorous scientific research and interdisciplinary learning.

Experience

Dr. Efthalia Moustakli is currently a Postdoctoral Researcher at the Department of Informatics and Telecommunications, University of Ioannina, focusing on molecular aging and bioinformatics. She also serves as an Adjunct Professor in the Nursing Department. Previously, she worked as a Junior Embryologist at Genesis Athens, a Molecular Biologist on the EU-funded PathAge project, and as a trainee in Germany at Universitätsklinikum Jena. Her experience spans clinical research, wet-lab diagnostics, data analysis, and teaching, highlighting her ability to navigate both academia and real-world clinical settings with excellence and innovation.

Awards 

Dr. Efthalia Moustakli has been recognized for her exceptional contributions to reproductive science and molecular biology, earning top academic grades in both her PhD and Integrated Master’s programs. Her work on oxidative stress, microRNAs, and genetic diagnostics has gained international attention through 30+ peer-reviewed publications. She has actively contributed to EU-funded research projects and presented findings at major conferences. Her unique blend of clinical embryology, teaching, and algorithm development distinguishes her as a well-rounded scientist. A strong candidate for the Best Researcher Award, she exemplifies academic rigor, innovation, and interdisciplinary impact.

Research Focus 

Dr. Efthalia Moustakli specializes in reproductive health, infertility, oxidative stress, NGS data meta-analysis, and clinical genetics. Her postdoctoral work delves into the molecular mechanisms of aging, particularly in relation to telomeres and mitochondrial function. Through projects like PathAge, she integrates computational approaches with clinical data to enhance diagnostic and therapeutic insights. Her research interests span microbiome impacts, ART (Assisted Reproductive Technology), and biomarkers for reproductive outcomes, aiming to translate molecular findings into practical healthcare improvements. She combines bioinformatics, wet-lab, and clinical insight to support advances in personalized and preventative medicine.

Publication Top Notes

chenguang zhang | Endocrine Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

chenguang zhang | Endocrine Pharmacology | Best Researcher Award

Dr. chenguang zhang at The Tumor Hospital of Xinjiang Medical University, China.

Dr. Chenguang Zhang 🧑‍⚕️ is a distinguished breast cancer surgeon and researcher, renowned for his expertise in diagnosing and treating both benign and malignant breast tumors. 🩺 He excels in surgeries including mastectomy, breast-conserving techniques, and reconstruction. 🧬 His cutting-edge research focuses on endocrine therapy resistance and molecular mechanisms in breast cancer, leading multiple high-level funded projects. 🔬 He holds a patent for surgical forceps 🛠️ and has authored numerous publications in SCI-indexed journals 📚. As a committed academic and member of several prestigious medical associations 🤝, Dr. Zhang is driving innovation in cancer diagnosis, treatment, and personalized care.

Publication Profile 

Orcid

Education

Dr. Chenguang Zhang 🧑‍⚕️ is highly proficient in the differential diagnosis of benign and malignant breast tumors 🔬. He is skilled in advanced breast cancer surgical techniques, including modified radical mastectomy, breast-conserving surgery, sentinel lymph node biopsy, and both implant-based and autologous tissue breast reconstruction 🏥. His research primarily targets the mechanisms behind endocrine therapy resistance in breast cancer 🎯. A leader in scientific innovation, he has directed multiple high-impact research projects at provincial and ministerial levels 🧪📊. Dr. Zhang’s commitment to precision medicine and surgical excellence is shaping the future of breast oncology care.

Professional Memberships

Dr. Chenguang Zhang 🧑‍⚕️ is an active contributor to the advancement of breast oncology through multiple prestigious professional memberships 🤝. He is a member of the Young Scholars Group of Breast Oncology under the Oncology Branch of the Chinese Medical Association 🧬, and serves on the Professional Committee of Oncoplastic Surgery within the China Anti-Cancer Association 🎗️. He is part of the Youth Expert Group 🌟 and the Young Scholars Group of the Science Popularization Branch of the Chinese Medical Doctor Association 📚. Additionally, he contributes to the Breast Minimally Invasive Plastic Surgery and Reconstruction Group within the Rehabilitation Society of the China Anti-Cancer Association.

Research Focus 

Dr. Chenguang Zhang’s research 🧪 focuses on breast cancer biology 🩺, particularly triple-negative breast cancer (TNBC) and endocrine therapy resistance in ER-positive tumors. His studies explore molecular pathways such as PI3K/AKT/mTOR, Wnt signaling, ferroptosis regulation, and autophagy inhibition 🧬. He investigates prognostic biomarkers, drug resistance mechanisms 💊, and advanced surgical strategies including sentinel lymph node biopsy and reconstructive techniques 🔬. His work contributes significantly to precision oncology, translational medicine, and clinical innovation in breast tumor management 🎗️. With a strong emphasis on molecular diagnostics, therapeutic resistance, and immunological responses, his research advances breast cancer treatment outcomes globally.

Publication Top Notes

  • Typical presentation of neurofibromatosis type I in a patient with giant cutaneous neoplasm and café au lait spots: A case report.
  • FOXO4 suppresses cisplatin resistance of triple-negative breast cancer by inhibiting autophagy.
  • Leveraging senescence-oxidative stress co-relation to predict prognosis and drug sensitivity in breast invasive carcinoma.
  • A degradome-based prognostic signature that correlates with immune infiltration and tumor mutation burden in breast cancer.
  • MET and FASN as Prognostic Biomarkers of Triple Negative Breast Cancer: A Systematic Evidence Landscape of Clinical Study.
  • HOXD Antisense Growth-Associated Long Noncoding RNA Promotes Triple-Negative Breast Cancer Progression by Activating Wnt Signaling Pathway.
  • Clinical study of combined application of indocyanine green and methylene blue for sentinel lymph node biopsy in breast cancer.
  • Expression and clinical significance of MAPK and EGFR in triple-negative breast cancer.
  • Expression analysis of E-cad and vascular endothelial growth factor in triple-negative breast cancer patients of different ethnic groups in western China.